Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 10/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924250 | 0.89 | CNR2 (0.46) | S1PR1PLA2G4A | |
| SCHEMBL3922098 | 0.84 | PLA2G4A (0.56) | PLA2G4A | |
| SCHEMBL3925406 | 0.82 | S1PR1 (0.48) | S1PR1SMN1; SMN2NPC1RAB9APLA2G4A | |
| SCHEMBL3931709 | 0.81 | PLA2G4A (0.56) | S1PR1SMN1; SMN2PLA2G4A | |
| SCHEMBL3919691 | 0.81 | PLA2G4A (0.56) | S1PR1SMN1; SMN2PLA2G4A | |
| SCHEMBL3920399 | 0.78 | PLA2G4A (0.58) | S1PR1PLA2G4A | |
| SCHEMBL3926819 | 0.78 | PLA2G4A (0.57) | S1PR1PLA2G4A | |
| SCHEMBL3933438 | 0.77 | S1PR1 (0.51) | S1PR1SMN1; SMN2PLA2G4AKMT2A | |
| SCHEMBL3921588 | 0.77 | CNR2 (0.43) | SMN1; SMN2PLA2G4AKMT2A | |
| SCHEMBL3929497 | 0.77 | PLA2G4A (0.55) | S1PR1SMN1; SMN2RAB9APLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608633-B2 | Heteroaryl-substituted acetone derivatives as inhibitors of phospholipase A2 | MERCKLE GMBH (DE) | 2009-10-27 | — | — | US | disclosed |
| EP-1590324-B1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A sb 2 /sb | MERCKLE GMBH (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142366-A1 | Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | MERCKLE GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142366-A1 | Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | PLD2, PLA2G1B, PLA2G4A | S1PR1 1120/4885SMN1; SMN2 4624/4885NPC1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.